AUTHOR=Wang Huan-Ping , He Jun-Jun , Zhu Qiao-Yun , Wang Lin , Li Jian-Hu , Huang Jian-Song , Xie Wan-Zhuo , Zhu Hong-Hu , Jin Jie 

TITLE=Case Report: The First Report of NUP214-ABL1 Fusion Gene in Acute Myeloid Leukemia Patient Detected by Next-Generation Sequencing

JOURNAL=Frontiers in Oncology

VOLUME=11

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.706798

DOI=10.3389/fonc.2021.706798

ISSN=2234-943X

ABSTRACT=<p>The <italic>NUP214-ABL1</italic> fusion gene is a constitutively active tyrosine kinase that can be detected in 6% of T-cell acute lymphoblastic leukemia (T-ALL) patients, and it can also be found in B-cell acute lymphoblastic leukaemia (B-ALL). However the <italic>NUP214-ABL1</italic> fusion in acute myeloid leukemia (AML) has not yet been reported. Up to now, the sensitivity of <italic>NUP214-ABL1</italic>-positive patients to tyrosine kinase inhibitor (TKI) is still controversial. Here we report the first case of an AML patient carrying <italic>NUP214-ABL1</italic> fusion gene. The conventional AML chemotherapy regimen for the patient was successful. Identification of additional AML patients with <italic>NUP214-ABL1</italic> fusion gene will provide treatment experience and prognostic evaluation.</p>